Loading clinical trials...

Evaluation of Effect of Integrated Treatment by Traditional Chinese and Western Medicine for Severe Acute Pancreatitis | Clinical Trials | Clareo Health

UNKNOWNPHASE2/PHASE3

Evaluation of Effect of Integrated Treatment by Traditional Chinese and Western Medicine for Severe Acute Pancreatitis

NCT00506337•Tianjin Nankai Hospital

View on ClinicalTrials.gov

Summary

With multicenter randomized control clinical evaluation investigations, the scheme of integrated medicine treatment of severe acute pancreatitis (SAP) was further improved, and the therapeutic effects, safety and indications assured. Drawing in latest research fruits at home and abroad, a clinical practical guideline for integrated medicine of diagnosis and treatment of SAP would be formed, to be popularized all over China.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patients 18yr-70yr, complying with the diagnostic standard of acute pancretitis (clinical symptoms and signs, elevated blood and urine amylase, and imaging criteria), conforming to 3 or more Ranson's criteria and APACHE-II score larger than 8, Balhazar CT score larger than 5.

Exclusion Criteria

•Pregnancy, nursing mother, critical cases of advanced tumor, on the verge of death (estimated to be moral in 12h), severe visceral function disturbance, patients undergoing other therapeutic research that might interfere with the present study.

Locations (3)

The 1st Affiliated Hospital, Dalian Medical Unversity

Dalian, Liaoning, China

West China Hospital, Sichuan Unversity

Chengdu, Sichuan, China

Tianjin Nankai Hospital

Tianjin, China

Key Dates

Start Date

October 1, 2006

Completion Date

October 1, 2009

Last Updated

July 31, 2007

Enrollment

300

ESTIMATED participants

Conditions

Pancreatitis, Acute Necrotizing

Interventions

Qingyi granules

DRUG

Contacts

Naiqiang Cui, Dr

CONTACT

+86 22 27022268 cuinq@sohu.com

Strategic Timing of Endoscopic Interventions in Infected Necrotizing Pancreatitis

NCT07406698

Pancreatitis, Acute Necrotizing

View study

COMPLETEDPHASE4

Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis

NCT02473406

Pancreatitis, Acute Necrotizing

View study

UNKNOWNNA

Dual-scopic Pancreatic Necrosectomy (DPN)

NCT04443595

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 31, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of Effect of Integrated Treatment by Traditional Chinese and Western Medicine for Severe Acute Pancreatitis

Inclusion Criteria

Exclusion Criteria

Strategic Timing of Endoscopic Interventions in Infected Necrotizing Pancreatitis

Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis

Dual-scopic Pancreatic Necrosectomy (DPN)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults

A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died

The Study of Laparoscopic-assisted Percutaneous Catheter-directed Drainage to Treat Early Severe Acute Pancreatitis